Pharmacogenomic Effect/ADR for Cetuximab (DBSNPE000153)

DocumentationBrowse all
Identifier
DBSNPE000153
Drug
Cetuximab (DB00002)
Interacting Gene/Enzyme
Low affinity immunoglobulin gamma Fc region receptor II-a
Gene Name
FCGR2A
UniProt ID
P12318
Defining Change(s)
H allellers1801274
Allele Name
Not Available
Genotype(s)
(C;T) / (T;T)
Type(s)
Effect Directly Studied
Groups
Not Available
Description
Patients with this genotype may have increased progression-free survival time when using cetuximab to treat colorectal cancer.
References
  1. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8. [Article]